New clinical research data on Glivec® in variety of cancers to be presented at American Society of Clinical Oncology meeting
Latest clinical research findings examine the potential of Glivec across a broad range of diseases
Basel, 27 May 2003 - New insights into the potential of Glivec® (imatinib) in treating a variety of cancers will be the focus of more than 70 abstracts presented this week at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois, USA. These data continue to show the promise of targeted therapies like Glivec in a wide range of clinical settings.
Please see full press release under the following link:
